

## Clinical & Patient Care Benefits of VSDP

**Better Clinical Decisions**: VSDP integrates all your diagnostic data (Optos imaging, OCT, ERG, refraction) into one longitudinal patient record with AI-powered analysis. Instead of hunting through multiple systems or relying on memory, you get predictive insights about disease progression and optimal intervention timing.

**Smarter Referral Decisions**: The platform uses algorithms to identify the *right time* to refer to specialists—not too early (wasting their time and your patient relationship) and not too late (risking worse outcomes). For glaucoma patients, for example, you can co-manage longer with AI-guided monitoring and refer only when objective risk thresholds are met.

**From Reactive to Proactive Care**: Digital twins enable you to shift from episodic visits to continuous monitoring. You can identify patients at risk before they walk in with problems, improving outcomes while strengthening patient relationships.

## Practice Operations & Efficiency

**Integrated Data Instead of System Chaos**: VSDP sits above your existing EHR, pulling together data from multiple devices and sources. No more switching between Optos software, OCT viewers, and your EHR—everything flows into one intelligent dashboard.

**Automated Documentation & Insights**: The platform can generate clinical summaries, track disease progression automatically, and flag patients who need follow-up. This reduces administrative burden that currently takes time away from patient care.

**Network Learning**: Your practice benefits from anonymized insights across all 3,000+ Vision Source practices. The AI gets smarter as the network grows, meaning better predictions and clinical support than any single practice could develop alone.

## Strategic Position

**Future-Proofing Your Practice**: While tech companies (Apple, Meta, Google) develop consumer vision monitoring devices, you maintain control of the clinical interpretation layer. You become the essential bridge between their data and patient health outcomes—they can't replace you, they need to partner with you.

**First-Mover Advantage**: As an early adopter in the Vision Source network, you'll have the most longitudinal data, the most refined AI models, and the strongest competitive position before this becomes table stakes in optometry.

**Input on Development**: Vision Source members have governance input on the product roadmap. You're not just buying software; you're co-creating the future of optometry practice.

## **The Context Problem: Current State**

Right now, when you see a patient, you're hunting and piecing together information:

**Multiple Systems, Zero Integration:**

- Open Optos software to view fundus images
- Switch to OCT viewer for retinal scans
- Check EHR for previous visit notes (hoping they're complete)
- Try to remember what happened at their last visit
- Maybe pull up lab results from their PCP if you're lucky
- Patient says "I have diabetes" but you have no idea what their glucose control looks like

**The Mental Gymnastics:**

- You're reconstructing their story from fragments every time they walk in
- Critical context is locked in other systems or just missing
- You make decisions based on incomplete snapshots, not the full picture
- Personalizing care requires you to manually track patterns across visits

**The Result:** You're providing care based on what you can *find* rather than what you *know* should inform your clinical decisions.

## **The VSDP Solution: Digital Twin as Universal Context**

VSDP creates a **computational model of each patient**—a "digital twin" that integrates everything relevant to their visual health in one place:

### **Automatic Data Aggregation**

The platform continuously pulls data from:

- **Clinical devices**: OCT, fundus imaging (Optos), autorefraction, tonometry, visual fields
- **External health data**: CGM readings (for diabetics), blood pressure, HbA1c labs, medications
- **Patient-reported data**: Symptoms, behaviors, screen time, environmental exposures
- **Historical patterns**: Every previous visit, progression trends, intervention responses

**The key difference:** You don't search for this information. It's already integrated, normalized, and presented as a unified patient state.

### **Intelligent Context Presentation**

When you open a patient's record, VSDP shows you:

**At-a-Glance Status:**

- Current risk scores for major conditions (glaucoma progression, diabetic retinopathy, myopia acceleration)
- Time-since-last measurements for critical metrics
- Flagged concerns that need attention
- Confidence levels on predictions (based on data quality and recency)

**Longitudinal Trends Visualized:**

- IOP progression over years, not just today's reading
- Retinal thickness changes mapped visually
- Glucose patterns correlated with retinal findings
- Intervention effectiveness tracked automatically

**Contextual Intelligence:**

- "This patient's glucose time-in-range dropped 15% since last visit—increased retinopathy risk"
- "Visual field stable for 18 months on current management—consider extending follow-up interval"
- "Similar patients in our network responded best to X treatment approach"

## **Personalization Through Continuous Learning**

### **Individual Pattern Recognition**

The digital twin learns *this specific patient's* patterns:

**Example - Myopia Management:**

- Traditional approach: Apply general guidelines (e.g., "outdoor time helps")
- VSDP approach: "This patient's progression correlates strongly with indoor screen time between 4-8pm, weakly with outdoor time. Their response to atropine was minimal compared to network average. Consider ortho-k based on their sleep patterns and parent compliance profile."

**Example - Glaucoma:**

- Traditional approach: Treat to target IOP based on population studies
- VSDP approach: "This patient's optic nerve shows progression even at IOP 14mmHg. Their digital twin indicates higher risk windows correlate with stress periods and poor sleep. Their medication adherence drops on weekends. Consider alternative delivery method or adjusted dosing schedule."

### **Network-Enhanced Insights**

Your patient benefits from the collective intelligence of 3,000+ practices:

**Comparative Analysis:**

- "Among 2,400 patients with similar baseline profiles, those who received intervention X showed 40% less progression"
- "Patients matching this risk profile typically require referral within 8 months—you're managing proactively"
- "This medication combination has 78% adherence rates in our network; consider alternatives with better real-world compliance"

**Predictive Personalization:** The twin runs "what-if" scenarios:

- "If we start treatment A now, predicted outcome in 12 months is..."
- "Waiting 6 months risks 35% probability of progression beyond our management threshold"
- "This patient's twin suggests they're in the 20% who respond exceptionally to treatment B"

## **The Clinical Impact: Real Examples**

### **Diabetic Patient (Sarah)**

**Traditional EHR View:**

- Type 2 diabetes, last HbA1c 8.2% (6 months ago)
- No diabetic retinopathy at last exam (1 year ago)
- Needs annual dilated exam

**VSDP Digital Twin View:**

- Real-time CGM data shows her time-in-range dropped from 65% to 48% over past 3 months
- Microaneurysm count increased from 2 to 7 in database image analysis
- Risk model predicts 72% probability of developing clinically significant DME within 18 months
- Her glucose variability pattern matches our highest-risk progression cohort
- **Recommendation**: Move to 4-month follow-up schedule, intensify diabetes management coordination with PCP, consider prophylactic anti-VEGF consultation

**Result:** You catch progression early because you had full context about her *current* metabolic state, not just her status 6-12 months ago.

### **Myopia Management (Jake, age 9)**

**Traditional Approach:**

- Baseline refraction: -2.50 D
- Prescribed ortho-k
- Return in 6 months to check progression

**VSDP Digital Twin:**

- Integrates parent-reported screen time data from app
- Tracks actual ortho-k wear compliance (sensor in case)
- Monitors outdoor time via phone location data (with consent)
- Compares his response to 1,200 similar patients in network
- Shows his progression rate is slowing but still above target
- Identifies that his screen time spikes correlate with faster progression weeks
- Network data shows patients with his profile respond better to combined atropine + ortho-k
- **Recommendation**: Add low-dose atropine, target 2+ hours outdoor time on school days (specific to his pattern), provide family with gamified outdoor activity app

**Result:** Personalized intervention based on *his specific patterns* rather than generic guidelines, with real-time monitoring to verify effectiveness.

Perfect. Here's the AMD patient example that shows the power of full context and personalization:

## **AMD Patient (Robert, age 73)**

### **Traditional EHR Approach:**

**What you see when Robert walks in:**

- Last visit: 14 months ago
- Diagnosis: Intermediate dry AMD, both eyes
- Visual acuity: 20/30 OD, 20/25 OS
- Drusen present in macula
- Recommended: AREDS2 vitamins, return annually

**What you have to do:**

- Pull up old fundus photos to compare (if you remember where they're saved)
- Try to recall if drusen have changed
- Ask Robert if he's taking his vitamins (he says "most days")
- Dilate and examine
- Make your best judgment about progression
- Schedule another annual visit

**What you're missing:**

- Has he actually been taking the vitamins consistently?
- What's his diet been like? (Smoking status? Cardiovascular health?)
- Are there subtle changes you can't detect by memory alone?
- Is he at higher or lower risk than average AMD patients?

### **VSDP Digital Twin Approach:**

**What the platform shows you automatically:**

**Integrated Risk Dashboard:**

```
ROBERT M. - Age 73 - MRN #8472
AMD Risk Score: 68/100 (↑ from 52 six months ago)

⚠️ HIGH PRIORITY ALERTS:
• Drusen volume increased 23% (automated image analysis)
• Geographic atrophy (GA) risk: 45% within 24 months
• Retinal pigment changes detected in temporal macula (AI flagged)
```

**Comprehensive Context Panel:**

**Visual Structure Tracking:**

- Automated drusen mapping across 8 visits over 4 years
- Volume: 0.08mm³ → 0.14mm³ → 0.21mm³ (accelerating)
- Pattern analysis: Confluent drusen developing in central macula
- OCT thickness maps showing RPE thinning
- Comparison to 2,400 similar AMD patients in network: "This progression rate places him in top 15% risk category"

**Lifestyle & Systemic Health Integration:**

- AREDS2 adherence: 60% based on pharmacy refill data (he's been skipping doses)
- Cardiovascular data from PCP's EHR:
  - Uncontrolled hypertension (BP averaging 145/92)
  - LDL cholesterol 160 mg/dL
  - Former smoker (quit 8 years ago, but 40-pack-year history)
- Diet tracking (patient-reported via app): Low in leafy greens, high in processed foods
- Activity level: Sedentary (step count averaging 2,800/day)

**Genetic & Family History:**

- Brother diagnosed with wet AMD at age 68
- CFH Y402H risk allele positive (from optional genetic test he did 2 years ago)
- Network data: Patients with his genetic + lifestyle profile convert to wet AMD at 3x baseline rate

**Functional Status:**

- Patient-reported symptoms (monthly app check-ins):
  - Month 1: "No changes"
  - Month 3: "Sometimes words look slightly blurry"
  - Month 5: "Straight lines look a bit wavy when reading"
- Digital Amsler grid tests (done at home weekly):
  - Subtle distortion pattern emerging in right eye
  - Left eye stable

### **AI-Powered Personalized Insights:**

**Risk Prediction Model:**

```
CONVERSION TO WET AMD PROBABILITY:
Next 6 months:  18% (↑ from 8% last visit)
Next 12 months: 34%
Next 24 months: 58%

GEOGRAPHIC ATROPHY PROBABILITY:
Next 12 months: 22%
Next 24 months: 45%

Key Risk Factors Contributing:
1. Drusen volume acceleration (weight: 35%)
2. Genetic profile + family history (weight: 25%)
3. Poor AREDS2 adherence (weight: 18%)
4. Cardiovascular risk factors (weight: 15%)
5. Emerging metamorphopsia symptoms (weight: 7%)
```

**Comparative Network Analysis:**

```
Among 847 patients with similar baseline profiles:
• Those with your monitoring protocol: 32% conversion rate at 2 years
• Those with intensive protocol*: 19% conversion rate at 2 years
  (*monthly OCT, home monitoring, aggressive lifestyle modification)

Intervention Effectiveness Data:
• Patients who improved AREDS2 adherence to >90%: 28% risk reduction
• Patients who added Mediterranean diet: 31% risk reduction
• Combined interventions: 52% risk reduction in progression rate
```

**Personalized Treatment Recommendation:**

The digital twin runs scenario simulations:

```
RECOMMENDED INTERVENTION PATHWAY:

Immediate Actions:
1. Switch to monthly OCT monitoring (not annual)
   - Network data: Early wet AMD detection reduces vision loss by 67%
   - Cost: Covered by Medicare for high-risk patients
   
2. Home monitoring kit enrollment
   - Digital Amsler grid 3x/week
   - Vision Source app with automated alerts
   - Patient training video: 8 minutes
   
3. Urgent AREDS2 adherence intervention
   - Switch to pre-packed daily doses (improves adherence to 88%)
   - Pharmacist consultation ($0 copay under Medicare)
   
4. Cardiovascular optimization coordination
   - Auto-generate secure message to PCP about HTN/cholesterol
   - Your risk model shows 15% AMD risk reduction with CV control
   
5. Dietary modification program
   - Mediterranean diet reduces progression 31% in network data
   - Refer to Vision Source nutrition partner (telehealth, covered)

Expected Outcomes (12-month projection):
• Standard annual monitoring: 34% wet AMD conversion risk
• Intensive monitoring alone: 26% risk
• Full intervention protocol: 16% risk
• Potential vision preservation: 2-3 lines of acuity

Monitor for wet conversion indicators:
- Sudden vision changes
- New/worsening distortion  
- Intraretinal/subretinal fluid on OCT
- ALERT THRESHOLD: Auto-schedule retina specialist within 48 hours
```

### **The Clinical Conversation Changes Completely:**

**Instead of:** "Robert, your AMD looks about the same. Keep taking those vitamins. See you next year."

**You can now say:** "Robert, I need to talk with you about some concerning changes. Our AI analysis has been tracking your drusen, and they've grown 23% since we last saw you—that's faster than we'd like to see. Combined with the symptoms you've been reporting in the app about wavy lines, your genetic risk factors, and honestly the fact that you've been missing doses of your vitamins, your risk of converting to wet AMD has jumped significantly.

The good news is we have data from hundreds of patients just like you, and we know exactly what works. If we move to monthly monitoring and get you on a more intensive prevention program—better vitamin adherence, some diet changes, and coordination with your primary doctor on your blood pressure—we can cut your risk in half.

I'm not willing to just watch and wait anymore. Let's be aggressive about protecting your vision. I'm going to set you up with our home monitoring kit, get you switched to a better vitamin delivery system, and we'll check your macula every month instead of every year. If we catch any conversion early, we can save your vision. Does that make sense?"

### **The Outcome:**

**Six months later:**

- Monthly OCT monitoring detected early choroidal neovascularization (CNV) at the second visit
- Referred to retina specialist within 48 hours
- Anti-VEGF injections started immediately
- Vision stabilized at 20/30 (would have been 20/200+ with annual monitoring)
- Patient now 92% adherent to AREDS2 (automated pill pack system)
- Blood pressure controlled, Mediterranean diet adopted
- Digital twin shows decreased progression risk for fellow eye

**Two years later:**

- Right eye: Treated wet AMD, stable at 20/30
- Left eye: Still dry AMD, but slower progression than predicted
- Patient avoided legal blindness
- Total healthcare cost savings: ~$180,000 (avoided advanced wet AMD bilateral treatment costs)
- Patient quality of life: Preserved independence, still driving



## **The Mental Shift**

**From:** "Let me search my EHR and try to remember what's happening with this patient"

**To:** "The digital twin presents complete context automatically, predicts what I need to know, and recommends personalized interventions based on this specific patient's patterns and our network's collective learning"

You stop being an information archaeologist and become a strategic clinical decision-maker with full context always at your fingertips.

## The Bottom Line

VSDP transforms your practice from a traditional exam provider into a visual system performance optimizer. You gain better clinical tools, reduce administrative frustration, create new revenue opportunities, and position yourself ahead of market disruption—all while paying half what external practices will pay and receiving profit sharing from the broader platform business.



